<qa>  What is the specific aims of the proposed clinical trial?Chronic HCV infection frequently causes neurocognitive NC and mood disorders but whether these disorders are caused by HCV or by the concomitant substance use and liver disease is unclear. Response to treatment has been obscured by the neurotoxicity of interferon-based HCV therapies. Newer DAAs are not neurotoxic and are expected to treat HCV-induced brain injury. However, clinical trials have yet to be performed to determine their CNS benefits. This presents a critical barrier to progress in the field that the proposed clinical trial will directly address. The specific aims will be to: 